These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38159497)

  • 1. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor.
    Sun Y; Chen Z; Liu G; Chen X; Shi Z; Feng H; Yu L; Li G; Ding K; Huang H; Zhang Z; Xu S
    Bioorg Chem; 2024 Feb; 143():107053. PubMed ID: 38159497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.
    Elsner J; Cashion D; Robinson D; Bahmanyar S; Tehrani L; Fultz KE; Narla RK; Peng X; Tran T; Apuy J; LeBrun L; Leftheris K; Boylan JF; Zhu D; Riggs JR
    J Med Chem; 2021 Sep; 64(17):12670-12679. PubMed ID: 34459599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
    Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
    J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
    Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
    Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
    Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
    Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
    M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
    J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
    Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
    Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
    Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
    Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
    Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68.
    Wei JH; Chou YF; Ou YH; Yeh YH; Tyan SW; Sun TP; Shen CY; Shieh SY
    J Biol Chem; 2005 Mar; 280(9):7748-57. PubMed ID: 15618221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
    Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
    PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.
    Liu Y; Zhu K; Guan X; Xie S; Wang Y; Tong Y; Guo L; Zheng H; Lu R
    J Ovarian Res; 2021 Oct; 14(1):128. PubMed ID: 34598710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
    Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
    Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
    Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of
    Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis underlying resistance to Mps1/TTK inhibitors.
    Koch A; Maia A; Janssen A; Medema RH
    Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
    Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.